Protocol Ledger

NCT06680505 · Phase II · COMPLETED

Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder

Interventional Phase II clinical trial protocol NCT06680505 sponsored by Shanghai Haiyan Pharmaceutical Technology Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-04 Enrollment: 300 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06680505
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06680505
Protocol FieldVerified Registry Value
NCT IdentifierNCT06680505
Consolidated Lead SponsorShanghai Haiyan Pharmaceutical Technology Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment300 participants (ACTUAL)
Registered Start Date2019-08-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI